NVSEF — NOVARTIS AG
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1114448 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,951,000,000 | 11,241,000,000 | 4,750,000,000 | 3,264,000,000 | 122,033,000,000 | 7,616,000,000 | 80,087,000,000 |
| Mar 2026 | 13,524,000,000 | 10,065,000,000 | 4,235,000,000 | 3,156,000,000 | 118,532,000,000 | 6,877,000,000 | 79,605,000,000 |
| Dec 2025 | 13,860,000,000 | 10,249,000,000 | 3,616,000,000 | 2,409,000,000 | 110,949,000,000 | 11,435,000,000 | 64,400,000,000 |
| Sep 2025 | 14,358,000,000 | 10,819,000,000 | 4,501,000,000 | 3,928,000,000 | 107,289,000,000 | 9,556,000,000 | 62,537,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$18,393,000,000
Investing CF
$-17,805,000,000
Financing CF
$453,000,000
CapEx
$-3,413,000,000
Dividends Paid
$-11,553,000,000
Buybacks
$-6,856,000,000
EPS Diluted TTM
$6.67
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$39,649,000,000
Inventory
$6,220,000,000
Receivables
$9,854,000,000
ST Investments
$74,000,000
EBIT TTM
$16,912,000,000
Pretax Income TTM
$15,522,000,000
Interest Exp TTM
$1,390,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,692,998,144
EBITDA
$23,097,999,360
Free Cash Flow
$11,900,250,112
Enterprise Value
$303,651,979,264
Total Cash
$7,617,999,872
Total Debt
$49,014,001,664
Shares Out
1,900,714,840
Trailing EPS
$6.63
Book Value
$21.86
ROE
30.3%
ROA
10.2%
Div Yield
3.43%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 56,674,000,000 | 17,644,000,000 | 13,984,000,000 | 110,949,000,000 | 64,400,000,000 | 46,130,000,000 | 19,144,000,000 |
| Dec 2024 | 51,722,000,000 | 14,544,000,000 | 11,941,000,000 | 102,246,000,000 | 58,120,000,000 | 44,046,000,000 | 17,619,000,000 |
| Dec 2023 | 46,660,000,000 | 9,769,000,000 | 14,850,000,000 | 99,945,000,000 | 53,195,000,000 | 46,667,000,000 | 14,458,000,000 |
| Dec 2022 | 43,461,000,000 | 7,946,000,000 | 6,955,000,000 | 117,453,000,000 | 58,030,000,000 | 59,342,000,000 | 14,236,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
Melexis (ENXTBR:MELE) Stock May Be 27% Undervalued As Cash Flow Holds Up
2026-10-09 17:21 · Yahoo
Cancer Stocks to Consider as Oncology Innovation Accelerates
2026-10-09 14:03 · Yahoo
Suominen’s financial reporting in 2027
2026-10-09 08:00 · Yahoo
Barclays downgrades 2 European airline stocks into September quarter results
2026-10-09 07:35 · Yahoo
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
2026-10-08 20:21 · Yahoo
Argenx Stock Sinks on Scrapped Autoimmune Drug Trial. Why the Selloff Is Overdone.
2026-10-08 17:23 · Yahoo
INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF SEPTEMBER 30, 2026
2026-10-08 15:45 · Yahoo
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
2026-10-08 15:19 · Yahoo
Pheochromocytoma and Paraganglioma (PCPG) Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted and Radioligand Therapies
2026-10-08 10:30 · Yahoo
VERBUND AG: Stefan Waldner Appointed Chief Financial Officer
2026-10-07 20:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.